Mass. General study reveals how MRSA infection compromises lymphatic function

January 17, 2018

Infections of the skin or other soft tissues with the hard-to-treat MRSA (methicillin-resistant Staphylococcus aureus) bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. In their report published online in Science Translational Medicine, Massachusetts General Hospital (MGH) investigators describe finding that MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.

"We found that MRSA produces toxins that kill the muscle cells critical to the pumping of lymph," says Timothy Padera, PhD, of the Steele Laboratories for Tumor Biology in the MGH Department of Radiation Oncology, senior author of the report. "MRSA with a genetic deficiency that lowers the amount of toxin produced does not kill lymphatic muscle cells, which both supports the role for bacterial toxins in the post-MRSA impairment of lymphatic function and may also suggest a possible treatment strategy."

Serious skin infections called cellulitis are reported in about 14 million U.S. patients annually, as many as 30 percent caused by MRSA. Serious cases requiring intravenous antibiotics lead to 500,000 hospitalization each year, and 50,000 of those patients will have recurrent infections that require hospital readmission within a month. Patients with lymphedema - swelling and fluid buildup caused by damage to or blockage of the lymphatic system - are particularly prone to recurrent infections, which can exacerbate existing lymphedema. But until now, no studies have investigated the potential interactions between bacterial infections and lymphatic function.

In contrast to the cardiovascular system, in which blood is propelled through arteries and veins by the pumping of the heart, in the lymphatic system, lymphatic fluid - which carries immune cells and other important factors - is pumped along by the contraction of the lymphatic vessels, driven by lymphatic muscle cells. Experiments in mouse models of MRSA tissue infections - conducted by team members including lead author Dennis Jones, PhD - revealed that the infection itself cleared within 30 days and associated inflammation was gone within 60 days. But the lymphatic vessels in MRSA-infected tissues showed abnormalities - including increased vessel diameter and weaker, less frequent contractions - that were still present 120 days after the induction of infection. Close examination revealed that the number of lymphatic muscle cells surrounding lymphatic vessels was depleted as late as 260 days after infection.

"We had assumed that we would find results similar to our previous measures of impaired lymphatic function in inflammation that was not associated with an infection," says Padera. "But while lymph pumping was restored after the resolution of sterile inflammation, MRSA-induced impairment persisted long after the infection was resolved and the inflammation had stopped. This persistence long after bacteria have been cleared can be explained by the loss of lymphatic muscle cells."

Exposure of cultured mouse and human lymphatic or smooth muscle cells to the proteins produced by MRSA led to the death of these cells, and detailed analysis of MRSA-produced proteins identified a significant number of known pathogenic toxins. Since expression of many MRSA toxins is controlled by a genetic element called the accessory gene regulator (agr), the team tested a mutant form of MRSA lacking the agr against several types of cultured cells and in their animal model. The agr-mutant MRSA did not produce the muscle-cell-killing proteins, and lymphatic function - including the strength and frequency of vessel contraction - was significantly better in mice infected with the mutant strain than in animals infected with a non-mutated strain.

"Our results strongly suggest that targeting the action of the agr during and after MRSA infection may preserve lymphatic muscle cells and, as a result, lymphatic function," says Padera, who is an associate professor of Radiation Oncology at Harvard Medical School. "Now we need to confirm whether MRSA infection leads to impaired lymphatic function in humans and identify the specific MRSA toxins that cause the death of lymphatic muscle cells."
-end-
Additional co-authors of the Science Translational Medicine paper are Eelco Meijer, MD, PhD, Shan Liao PhD, Ethel Pereira, PhD, Echoe Bouta, PhD, Keehoon Jung, PhD, Shan Min Chin, Peigen Huang, MD, and Lance Munn, PhD, Steele Laboratories, MGH Radiation Oncology; Cedric Blatter, PhD, and Benjamin Vakoc, PhD, MGH Wellman Center for Photomedicine; and Michael Otto, PhD, National Institute for Allergy and Infectious Diseases. Support for the study includes National Institutes of Health grants R21 AI097745, DP2 OD008780, R01 CA214913 and R01HL128168, along with support from the MGH Executive Committee on Research Interim Support Fund.

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $900 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, genomic medicine, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology. The MGH topped the 2015 Nature Index list of health care organizations publishing in leading scientific journals and earned the prestigious 2015 Foster G. McGaw Prize for Excellence in Community Service. In August 2017 the MGH was once again named to the Honor Roll in the U.S. News & World Report list of "America's Best Hospitals."

Massachusetts General Hospital

Related MRSA Articles from Brightsurf:

Widely available antibiotics could be used in the treatment of 'superbug' MRSA
Some MRSA infections could be tackled using widely-available antibiotics, suggests new research from an international collaboration led by scientists at the University of Cambridge and the Wellcome Sanger Institute.

Computer model shows how to better control MRSA outbreaks
A research team led by scientists at the Columbia University Mailman School of Public Health report on a new method to help health officials control outbreaks of methicillin-resistant Staphylococcus aureus, or MRSA, a life-threatening antibiotic-resistant infection often seen in hospitals.

Using MRSA's strength against it
MRSA evolved to become a deadly killer because it's wily and resilient.

Livestock-associated MRSAfound among MRSA from humans
The survey results show more frequent detections and geographical dispersion of LA-MRSA in humans in the EU/EEA since 2007, and highlight the public health and veterinary importance of LA-MRSA as a 'One Health' issue.

Fighting MRSA with new membrane-busting compounds
Public health officials are increasingly concerned over methicillin-resistant Staphylococcus aureus (MRSA).

Know thy enemy: Kill MRSA with tailored chemistry
UConn medicinal chemists have developed experimental antibiotics that kill MRSA, a common and often deadly bacteria that causes skin, lung, and heart infections.

MRSA uses decoys to evade a last-resort antibiotic
The superbug MRSA uses decoys to evade a last-resort antibiotic, reveals new research.

Scientists find a salty way to kill MRSA
Scientists have discovered a new way to attack Staphylococcus aureus bacteria.

Experimental antibiotic treats deadly MRSA infection
A new experimental antibiotic developed by a team of scientists at Rutgers University successfully treats the deadly MRSA infection and restores the efficacy of a commonly prescribed antibiotic that has become ineffective against MRSA.

OU team develops new antibiotic to fight MRSA
A University of Oklahoma team of chemists has developed a new antibiotic formulation to fight the sometimes deadly staph infection caused by methicillin-resistant S. aureus or MRSA and other antibiotic-resistant infectious bacteria.

Read More: MRSA News and MRSA Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.